Analytical Data
-
基因名
Mageh1
- Application
-
别名
(MAGE-H1 antigen)
-
种属
Mouse
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NWG9
-
表达区间
1-218aa
-
分子量
30.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Mageh1 (Melanoma-associated antigen H1) is a member of the MAGE (melanoma-associated antigen) family, which is known for its role in tumorigenesis and immune response. Discovered in the context of melanoma, Mageh1 has garnered attention due to its potential as a target for cancer immunotherapy, particularly in solid tumors. The protein is believed to be involved in the modulation of cell cycle regulation and apoptosis, making it a critical player in cancer development. Research has focused on its expression patterns, as Mageh1 is typically found in various tumors but not in most normal tissues, highlighting its potential as a tumor-specific antigen. Advances in recombinant protein technology have enabled the production of Mageh1 in a laboratory setting, facilitating studies on its structure, function, and interactions with immune cells. Understanding the properties of Mageh1 recombinant protein is essential for the development of therapeutic strategies, including peptide-based vaccines and adoptive T-cell therapies. Current studies aim to elucidate the immunogenicity of Mageh1 and its potential to stimulate an effective antitumor immune response, paving the way for novel cancer immunotherapies that harness the body's immune system to target and eliminate malignant cells.
